2.50
Hdl Handle:
http://hdl.handle.net/10541/66157
Title:
Antiangiogenic drugs in ovarian cancer.
Authors:
Kumaran, Gireesh C; Jayson, Gordon C ( 0000-0002-8515-8944 ) ; Clamp, Andrew R
Abstract:
Ovarian cancer continues to be a major cause of morbidity and mortality in women. Antiangiogenic treatments have emerged as a promising strategy to treat ovarian cancer. This article reviews the rationale supporting the use of antiangiogenic treatments in ovarian cancer, the clinical development of this group of drugs and the toxicities specific to this modality of treatment.
Affiliation:
Department of Medical Oncology, Cancer Research UK, Manchester, UK. gkumaran@picr.man.ac.uk
Citation:
Antiangiogenic drugs in ovarian cancer. 2009, 100 (1):1-7 Br. J. Cancer
Journal:
British Journal of Cancer
Issue Date:
13-Jan-2009
URI:
http://hdl.handle.net/10541/66157
DOI:
10.1038/sj.bjc.6604767
PubMed ID:
19002176
Type:
Article
Language:
en
ISSN:
1532-1827
Appears in Collections:
All Paterson Institute for Cancer Research; Medical Oncology

Full metadata record

DC FieldValue Language
dc.contributor.authorKumaran, Gireesh C-
dc.contributor.authorJayson, Gordon C-
dc.contributor.authorClamp, Andrew R-
dc.date.accessioned2009-04-24T09:01:52Z-
dc.date.available2009-04-24T09:01:52Z-
dc.date.issued2009-01-13-
dc.identifier.citationAntiangiogenic drugs in ovarian cancer. 2009, 100 (1):1-7 Br. J. Canceren
dc.identifier.issn1532-1827-
dc.identifier.pmid19002176-
dc.identifier.doi10.1038/sj.bjc.6604767-
dc.identifier.urihttp://hdl.handle.net/10541/66157-
dc.description.abstractOvarian cancer continues to be a major cause of morbidity and mortality in women. Antiangiogenic treatments have emerged as a promising strategy to treat ovarian cancer. This article reviews the rationale supporting the use of antiangiogenic treatments in ovarian cancer, the clinical development of this group of drugs and the toxicities specific to this modality of treatment.en
dc.language.isoenen
dc.subjectOvarian Canceren
dc.subjectBiomarkersen
dc.subjectAdverse Effectsen
dc.subject.meshAngiogenesis Inhibitors-
dc.subject.meshAntibodies, Monoclonal-
dc.subject.meshEndothelial Cells-
dc.subject.meshFemale-
dc.subject.meshHumans-
dc.subject.meshNeovascularization, Pathologic-
dc.subject.meshOvarian Neoplasms-
dc.subject.meshOvary-
dc.subject.meshReceptors, Vascular Endothelial Growth Factor-
dc.subject.meshVascular Endothelial Growth Factor A-
dc.titleAntiangiogenic drugs in ovarian cancer.en
dc.typeArticleen
dc.contributor.departmentDepartment of Medical Oncology, Cancer Research UK, Manchester, UK. gkumaran@picr.man.ac.uken
dc.identifier.journalBritish Journal of Canceren

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.